News | December 03, 2006

Novel Polymer-free DES Showing Promise

Two novel polymer-free drug-eluting stent coating technologies tested in a comparative animal study has concluded with positive results, according to a release from Atlanta-based MIV Therapeutics.

A developer of next-generation biocompatible polymer-free DES and advanced drug delivery systems, MIVT says the study compared stents coated with its polymer-free drug-eluting technologies to the J&J Cypher stent and successfully demonstrated that both of MIVT's proprietary, polymer-free, Sirolimus eluting coatings are at least as good as Cypher. The study also demonstrated MIVT's coatings' potential and efficacy when compared to Cypher(TM).

Dr Willem J. van der Giessen, MD, PhD, Interventional Cardiologist and Dr. Heleen M.M van Beusekom, PhD, Experimental Cardiology, from the Thoraxcenter at the Erasmus University Medical Center were the study directors. The objectives of the study were to evaluate the safety of MIVT's Hydroxyapatite coating and to assess the efficacy of MIVT Sirolimus coated stents in a porcine coronary model.

The results from the first part of the study, conducted with no drug added to the coatings, showed that HAp coated stents and bare metal stents did best and performed equally well.

The results from the second part of the study, with drugs added to the coatings, showed that all of the MIVT drug-eluting technologies performed at least as well, and in some cases better than the industry's benchmark, the J&J Cypher(TM) stent.

MIV Therapeutics is developing a diverse suite of Polymer-Free HAp coating formulas to improve the biocompatibility of stents and other implantable medical devices. Hydroxyapatite (HAp) occurs naturally in human bones and teeth. It rapidly integrates into the human body and has been shown to have excellent stability and biocompatibility. HAp is non-toxic, non-thrombogenic, non-inflammatory and has been shown to promote angiogenesis. HAp coatings are also expected to reduce the increased risk of deadly blood clots currently associated with today's polymeric drug-eluting stents.

The company says it plans to begin the first human implants of a HAp Nano Film Coated stent early in 2007. Human implantation represents a significant milestone in MIVT's strategic plan to develop a new class of polymer-free drug-eluting stents that could provide patients with superior outcomes.

Related Content

Biotronik Symposium Highlights Differing Roles of Drug-Eluting Stents and Magnesium Scaffolds in Clinical Practice
News | Stents Drug Eluting | January 25, 2018
January 25, 2018 – Data presented at the Biotronik-sponsored...
The Abbott Absorb Bioresorbable Vascular Scaffold (BVS) bioabsorbable stent.

The Abbott Absorb Bioresorbable Vascular Scaffold (BVS).

Feature | Stents Drug Eluting | January 17, 2018 | Dave Fornell
There was no shortage of interest in bioresorbable stent technologies at the many sessions offered on this topic or b
Cordis and Medinol Announce FDA Approval of EluNIR Drug-Eluting Stent System
Technology | Stents Drug Eluting | December 13, 2017
Cordis, a Cardinal Health company, and Medinol recently announced U.S. Food and Drug Administration (FDA) approval of...
The Xience Sierra stent.
Technology | Stents Drug Eluting | November 09, 2017
November 9, 2017 — Abbott received European CE mark for Xience Sierra, the newest generation of the company's Xience
Synergy Stent With Shorter DAPT Superior to Bare-Metal Stent in Elderly Patients
News | Stents Drug Eluting | November 06, 2017
November 6, 2017 — Elderly patients undergoing...
Biotronik Orsiro DES Shows Low Five-Year Event Rates
News | Stents Drug Eluting | November 03, 2017
November 3, 2017 — Biotronik's Orsiro...
Three-Month DAPT Non-Inferior for ACS Patients Treated With Combo Dual Therapy Stent

Image courtesy of OrbusNeich

News | Stents Drug Eluting | November 01, 2017
OrbusNeich reported results from the REDUCE trial in the Late-Breaking Clinical Trial session at the 29th annual...
News | Stents Drug Eluting | October 25, 2017
Elixir Medical Corp. announced it will unveil a new metallic drug-eluting stent (DES) platform at this year’s...
Biotronik's Orsiro Drug-Eluting Stent Outperforms Xience in BIOFLOW-V Trial
News | Stents Drug Eluting | September 01, 2017
September 1, 2017 — Biotronik recently announced data from the BIOFLOW-V randomized trial comparing Orsiro and Xience
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting | May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Overlay Init